ACADIA (ACAD) director Garofalo exercises RSUs and receives new option, RSU awards
Rhea-AI Filing Summary
ACADIA PHARMACEUTICALS director Elizabeth A. Garofalo reported equity compensation activity centered on RSUs and stock options. On May 29, 2026, she exercised 8,107 restricted stock units into 8,107 shares of common stock, bringing her direct common stock holdings to 33,489 shares.
She also received a new grant of 9,311 restricted stock units, each representing one future share of common stock, and 16,004 director stock options with a strike price of $21.66 per share that vest quarterly over one year. The new RSUs will vest in full on the earlier of one year from grant or the next annual meeting, and she has elected to defer receipt of the underlying shares until specified future triggers.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 8,107 shares
Net Buy
4 txns
Insider
GAROFALO ELIZABETH A.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 8,107 | $0.00 | $0.00 |
| Grant/Award | Director Stock Options (Right to Buy) | 16,004 | $0.00 | $0.00 |
| Grant/Award | Restricted Stock Units | 9,311 | $0.00 | $0.00 |
| Exercise | Common Stock | 8,107 | $0.00 | $0.00 |
Holdings After Transaction:
Director Stock Options (Right to Buy) — 16,004 shares (Direct);
Restricted Stock Units — 9,311 shares (Direct);
Common Stock — 33,489 shares (Direct)
Footnotes (4)
- F1. Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
- F2. The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held.
- F3. The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders.
- F4. The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. The reporting person has elected to defer receipt of the shares of common stock underlying the restricted stock units until the earliest of the following: (i) the fifth anniversary of the date of grant of such restricted stock unit award; (ii) the date that is 30 days following the date on which the director ceases to serve as a member of the board of directors of the Issuer or otherwise provide services to the Issuer; and (iii) a change in control of the Issuer as defined in the Issuer's 2024 Equity Incentive Plan, as amended.
Key Figures
RSUs exercised: 8,107 shares
Common shares held: 33,489 shares
New RSU grant: 9,311 units
+2 more
5 metrics
RSUs exercised
8,107 shares
Restricted stock units converted to common stock on May 29, 2026
Common shares held
33,489 shares
Direct common stock holdings after transactions
New RSU grant
9,311 units
Restricted stock units granted on May 29, 2026
New options granted
16,004 options
Director stock options granted on May 29, 2026
Option exercise price
$21.66 per share
Strike price for director stock options expiring May 28, 2036
Key Terms
Restricted Stock Units, Director Stock Options, change in control, 2024 Equity Incentive Plan
4 terms
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Director Stock Options financial
"The shares subject to each stock option will vest quarterly over one year following the date of grant"
Stock options granted to a company’s board members that give those directors the right to buy company shares at a preset price after certain conditions are met. They matter to investors because they align directors’ incentives with shareholders—encouraging decisions that could raise the share price—but also create potential share dilution and future selling pressure once the options are exercised, similar to giving a delayed bonus tied to performance.
change in control financial
"and (iii) a change in control of the Issuer as defined in the Issuer's 2024 Equity Incentive Plan, as amended."
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
2024 Equity Incentive Plan financial
"as defined in the Issuer's 2024 Equity Incentive Plan, as amended."
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did ACAD (ACADIA PHARMACEUTICALS) director Elizabeth Garofalo report in this Form 4?
She reported equity compensation activity, including exercising 8,107 restricted stock units into common shares and receiving new grants of 9,311 restricted stock units and 16,004 director stock options, all held as direct ownership as of the reported date.
What restricted stock unit awards did ACAD director Garofalo receive on May 29, 2026?
She received 9,311 restricted stock units, each representing one future share of ACAD common stock. These RSUs vest in full on the earlier of one year from grant or the next annual meeting, with settlement deferred until certain specified future events.
What are the terms of Elizabeth Garofalo’s new ACAD director stock options?
She was granted 16,004 director stock options with an exercise price of $21.66 per share. The options vest quarterly over one year following the grant date, with the final tranche vesting by the earlier of one year or the next annual stockholder meeting.
How were previously granted ACAD restricted stock units treated in this filing?
Previously granted restricted stock units totaling 8,107 vested in full on May 29, 2026, the date of ACAD’s annual stockholder meeting, and were exercised into 8,107 common shares, reducing the RSU balance tied to that earlier award to zero.